Skip to main content
. 2019 Oct 7;33(1):3–16. doi: 10.1177/1971400919881188

Table 1.

Clinical and laboratory variables in TBM patients with cerebral infarcts (n = 52); and with and without cerebral infarcts (n = 90).

Variable TBM patients with cerebral infarcts (n = 52) TBM patients with and without cerebral infarcts (n = 90)
Age range; mean, y 10–82; 32.3 10–82; 32
 <40 years 39 (75%) 66 (73.3%)
 ≥40 years 13 (25%) 24 (27.7%)
Sex, Male:Female 26:26 42:48
Duration of symptoms mean (range), d 66 (3–240) 63.7 (2–240)
Clinical symptoms, n (%)
 Fever 52 (100%) 90 (100%)
 Headache 46 (88.4%) 76 (84.4%)
 Vomiting 33 (63.4%) 46 (51.1%)
 Seizures 10 (19.2%) 15 (16.6%)
 Altered sensorium 33 (63.4%) 48 (53.3%)
 Hemi/paraparesis/focal weakness 12 (23%) 20 (22.2%)
CSF parameters (n = 48) (n = 75)
 Cell count mm3, mean (range) 120 (20–635) 138 (6–733)
 Protein mg/dl 133 (44–495) 133 (44–495)
 Glucose mmol/l 1.54 (0.1–7.0) 1.54 (0.1–7.0)
Mycobacterial culture positive, n (%), 14/41 (34%) 18/62 (29%)
Tuberculous polymerase chain reaction, n (%) 5/41 (12%) 9/62 (14.5%)
Other tests for fungal and cryptococcal antigen 0/28 0/40
Diagnostic category
 Definite 12 (23%) 21 (23.3%)
 Probable 17 (32.7%) 33 (36.7%)
 Possible 23 (44.2%) 36 (40%)
TBM grade
 I 12 (23%) 26 (28.8%)
 II 27 (52%) 48 (53.3%)
 III 13 (25%) 16 (17.7%)
Comorbidities DM and HT/ALD/SLE/HIV 4/1/1/0 6/1/1/1
Extraneural involvement tuberculosis 12 (23%) (lung = 4, abdomen = 2, disseminated TB = 5, spine = 2) 19 (21%) (lung = 9, abdomen = 2, disseminated TB = 5, spine = 3)
Outcome Good outcome (mRS 0–2) 41/52 (78.8%) 73/90 (81.1%)
Poor outcome (mRS 3–6) 11/52 (21.1%) 4 died 17/90 (18.8%) 4 died
Neural biopsy 1 1

ALD: alcoholic liver disease; DM: diabetes mellitus; HIV: human immunodeficiency virus; HT: hypertension; mRS: modified Rankin scale; SLE: systemic lupus erythematosus; TBM: tuberculous meningitis; MRV-N: Magnetic Resonance Venography-Normal; MB= Midbrain.